News

According to investigators, the study demonstrated that by restoring the function of ADAM10, a major shedding protein, it was possible in preclinical models to control the abnormal formation of blood vessels, offering an attractive therapeutic target to treat DR.

Korean biotech company MDimune Inc. and scientists from the Clear Vision Research Lab at The Australian National University hope to turn recent research milestones into potential treatments for AMD.

Automated AI tool offers offline capability and hope for patients.

Derek Hodkey, president and CEO of Orbis International, discusses key achievements for the company and its Flying Eye Hospital in 2022 and offers his outlook for 2023.

The National Institute on Aging of the National Institutes of Health (NIH) is expanding the effort to understand that connection with a $10.3 million grant.

Resection techniques for choroidal tumours are based on modern vitreoretinal surgical techniques, which allow for the treatment of more challenging cases.

According to investigators, the study used curated real-world data from the IRIS Registry to report risk of progression by stage.

According to the company, clinical outcomes for 78 dry eye patients treated at a single center, the Cleveland Eye Clinic, showcased the duration of efficacy of a single, first-time treatment of MGD using the TearCare System.

The National Institute on Aging of the National Institutes of Health (NIH) is expanding the effort to understand that connection with a $10.3 million grant.

The company’s collaboration leverages MyEyeDr.’s 850+ offices across the United States to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are.

Wills Eye Hospital’s annual Give Kids Sight Day provides access to eyecare for children.

The study, co-led by Griffith University’s Menzies Health Institute and South Korea’s Center for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technology, aims to understand how SARS-CoV-2 affects the eyes and whether it could serve as a virus infection route.

The submission follows the U.S. FDA acceptance of the ONS-5010 BLA for wet AMD, with a PDUFA date of August 29, 2023.

In this preliminary study, researchers found that renal function might affect the response to IVBI treatment in patients with DME.

The study aims to understand how SARS-CoV-2 affects the eyes and whether it could serve as a virus infection route.

Heavy silicone oil tamponade in secondary surgery for persistent full-thickness macular holes is a safe and efficient surgical method. Best-corrected visual acuity and minimum linear diameter before surgery may be indicators for anatomical success.

The company said the submission follows the FDA acceptance of the ONS-5010 BLA for the treatment of wet AMD, with a PDUFA date of August 29, 2023.

According to University of Michigan investigators, the findings could help inform treatments for blindness in humans.

According to a team of investigators from the University of Michigan, the findings could help inform treatments for blindness in humans.

Scientists from the Clear Vision Research Lab at The Australian National University and the Korean biotech company MDimune Inc. hope to turn recent research milestones into potential treatments for AMD.

Retinopathy of prematurity is thought to be a two-stage disorder that begins with the arrested development of the retinal vessels in preterm babies when exposed to high oxygen levels at birth.

Lawmakers on Tuesday unveiled the $1.7 trillion proposed spending package needed to avert a government shutdown by Friday if both chambers can pass the measure this week.

Company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.

The Cell and Gene Therapy Center will combine a team of 100 researchers to capitalize on the company’s 35 years of cell and gene therapy experience.

Findings may help pediatricians and ophthalmologists to determine the appropriate timing of examinations and treatment.

On Tuesday, lawmakers unveiled the $1.7 trillion proposed spending package needed to avert a government shutdown by Friday if both chambers can pass the measure this week.

Parexel teams with MyEyeDr. to leverage MyEyeDr.’s 850+ offices across the United States to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are.

Previous research conducted primarily by scientists at the University of São Paulo, Brazil, showed brilacidin can potentiate several marketed antifungals, including caspofungin, voriconazole and posaconazole.